Author: Charles Ornstein, ProPublica, and Katie Thomas, The New York Times
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in medical research.
At a time when the United States is in the grip of an opioid epidemic, many insurers are limiting access to pain medications that carry a lower risk of addiction or dependence, even as they ...
Amid the public fury over the escalating costs of brand-name medications, the prices of generic drugs have been falling, raising fears about the profitability of major generic manufacturers. Last week, Teva Pharmaceuticals reported that it ...
Faced with competition, some pharmaceutical companies are cutting deals with insurance companies to favor their brand-name products over cheaper generics. Insurers pay less, but sometimes consumers pay more. Adderall XR, a drug to treat attention-deficit ...
Popular Posts
-
Watchdog Groups: Rick Santorum Illegally Directed Campaign FundsAugust 15, 2013 -
North Carolina Is Damaging The Republican BrandAugust 15, 2013 -
An Engineer Explains Why Trump’s Wall Is So ImplausibleSeptember 21, 2015
Latest Posts
